Eplerenone - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for eplerenone and what is the scope of freedom to operate?
Eplerenone
is the generic ingredient in two branded drugs marketed by Accord Hlthcare, Annora Pharma, Breckenridge, Chartwell Rx, Prasco, Rising, Sandoz, Slate Run Pharma, Westminster Pharms, and Upjohn, and is included in ten NDAs. Additional information is available in the individual branded drug profile pages.There are five drug master file entries for eplerenone. Fourteen suppliers are listed for this compound.
Summary for eplerenone
US Patents: | 0 |
Tradenames: | 2 |
Applicants: | 10 |
NDAs: | 10 |
Drug Master File Entries: | 5 |
Finished Product Suppliers / Packagers: | 14 |
Raw Ingredient (Bulk) Api Vendors: | 61 |
Clinical Trials: | 128 |
Patent Applications: | 5,485 |
Drug Prices: | Drug price trends for eplerenone |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for eplerenone |
What excipients (inactive ingredients) are in eplerenone? | eplerenone excipients list |
DailyMed Link: | eplerenone at DailyMed |
Recent Clinical Trials for eplerenone
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Assiut University | Phase 4 |
Vifor Pharma | Phase 3 |
Mario Negri Institute for Pharmacological Research | Phase 3 |
Pharmacology for eplerenone
Drug Class | Aldosterone Antagonist |
Mechanism of Action | Aldosterone Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for eplerenone
Paragraph IV (Patent) Challenges for EPLERENONE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
INSPRA | Injection | eplerenone | 0.75 mg/mL, 100 mL vial | 021437 | 1 | 2009-06-05 |
INSPRA | Tablets | eplerenone | 25 mg and 50 mg | 021437 | 2 | 2006-09-27 |
US Patents and Regulatory Information for eplerenone
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Rising | EPLERENONE | eplerenone | TABLET;ORAL | 214663-001 | Mar 23, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Westminster Pharms | EPLERENONE | eplerenone | TABLET;ORAL | 207842-001 | Oct 25, 2021 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Westminster Pharms | EPLERENONE | eplerenone | TABLET;ORAL | 207842-002 | Oct 25, 2021 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Annora Pharma | EPLERENONE | eplerenone | TABLET;ORAL | 213812-002 | Jun 2, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Slate Run Pharma | EPLERENONE | eplerenone | TABLET;ORAL | 212765-002 | Aug 10, 2020 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for eplerenone
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Upjohn | INSPRA | eplerenone | TABLET;ORAL | 021437-002 | Sep 27, 2002 | ⤷ Sign Up | ⤷ Sign Up |
Upjohn | INSPRA | eplerenone | TABLET;ORAL | 021437-002 | Sep 27, 2002 | ⤷ Sign Up | ⤷ Sign Up |
Upjohn | INSPRA | eplerenone | TABLET;ORAL | 021437-002 | Sep 27, 2002 | ⤷ Sign Up | ⤷ Sign Up |
Upjohn | INSPRA | eplerenone | TABLET;ORAL | 021437-001 | Sep 27, 2002 | ⤷ Sign Up | ⤷ Sign Up |
Upjohn | INSPRA | eplerenone | TABLET;ORAL | 021437-003 | Sep 27, 2002 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.